Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy
Open Access
- 24 November 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 15 (12), 1783-1791
- https://doi.org/10.1002/lt.21907
Abstract
Less potent immunosuppression is considered to reduce the severity of hepatitis C virus (HCV) recurrence after liver transplantation. An optimal regimen is unknown. We evaluated tacrolimus monotherapy versus triple therapy in a randomized trial of 103 first transplants for HCV cirrhosis. One hundred three patients who underwent transplantation for HCV were randomized to tacrolimus monotherapy (n = 54) or triple therapy with tacrolimus, azathioprine, and steroids (n = 49), which were tapered to zero by 3 to 6 months. Both groups had serial transjugular biopsies with hepatic venous pressure gradient (HVPG) measurement. The time to reach Ishak stage 4 was the predetermined endpoint. All factors documented in the literature as being associated with HCV recurrence and the allocated treatment were evaluated for reaching stage 4 and HVPG ≥ 10 mm Hg. No significant preoperative, perioperative, or postoperative differences, including the frequency of biopsies between groups, were found. During a mean follow‐up of 53.5 months, 9 monotherapy patients and 6 triple therapy patients died, and 5 monotherapy patients and 4 triple therapy patients underwent retransplantation. Stage 4 fibrosis was reached in 17 monotherapy patients and 10 triple therapy patients (P = 0.04), with slower fibrosis progression in the triple therapy patients (P = 0.048). Allocated therapy and histological acute hepatitis were independently associated with stage 4 fibrosis. HVPG increased to ≥10 mm Hg more rapidly in monotherapy patients versus triple therapy patients (P = 0.038). In conclusion, long‐term maintenance immunosuppression with azathioprine and shorter term prednisolone with tacrolimus in HCV cirrhosis recipients resulted in a slower onset of histologically proven severe fibrosis and portal hypertension in comparison with tacrolimus alone, and this was independent of known factors affecting fibrosis. Liver Transpl 15:1783–1791, 2009. © 2009 AASLD.Keywords
This publication has 59 references indexed in Scilit:
- Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradientTransplant International, 2008
- Risk factors for hepatitis C recurrence after liver transplantationJournal of Viral Hepatitis, 2007
- Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantationLiver Transplantation, 2007
- The Impact of Diabetes Mellitus on Fibrosis Progression in Patients Transplanted for Hepatitis CAmerican Journal of Transplantation, 2006
- Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantationLiver Transplantation, 2005
- Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-upTransplantation, 2004
- The natural history and outcome of liver transplantation in hepatitis C virus-infected recipientsLiver Transplantation, 2003
- A model to predict severe HCV-related disease following liver transplantationHepatology, 2003
- Impact of immunosuppressive therapy on recurrence of hepatitis CLiver Transplantation, 2002
- Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipientsHepatology, 2002